MTSL Issue 826

 Comments Off on MTSL Issue 826
May 012016
 
MTSL Issue 826

MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP

MTSL Issue 815

 Comments Off on MTSL Issue 815
Nov 152015
 
MTSL Issue 815

Issue No. 815 (dated 11/12/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #ACAD, #FPRX, #INCY, #ISIS, #MDCO, #NKTR, #NVAX, #OGXI, #XON

MarketWatch (5-13-15)

 Comments Off on MarketWatch (5-13-15)
May 142015
 
MarketWatch (5-13-15)

Biotech buyout fever is going to continue. But be careful: You need to pick the right companies and hold them for years. Find out the reasons biotech buyouts will continue and stock picks from biotech analysts including John McCamant of BioInvest.

Life Sciences Report (5-12-15)

 Comments Off on Life Sciences Report (5-12-15)
May 132015
 
Life Sciences Report (5-12-15)

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

Incyte Update (8-21-13)

 Comments Off on Incyte Update (8-21-13)
Sep 112013
 
Incyte Update (8-21-13)

Incyte’s Jakafi Delivers Great Phase II Pancreatic Data:  INCY has reported great top-line results from their Phase II, randomized, double-blind, placebo-controlled RECAP trial of Jakafi in combination with capecitabine in patients with recurrent or treatment refractory metastatic pancreatic cancer. The hazard ratio (HR) for overall survival (OS) in the intent to treat population was 0.79 […]

Incyte Update (8-8-13)

 Comments Off on Incyte Update (8-8-13)
Aug 122013
 
Incyte Update (8-8-13)

INCY – Q2 Beats Street On Jakafi & Raises 2013 Forecast, Burgeoning Pipeline – Raising BUY LIMIT and PRICE TARGET. The key near-term driver for INCY is Jakafi growth and with the increased sales guidance, the company is delivering.  The drug’s overall profile continues to improve as witnessed by label expansion for patients with low […]